Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 8/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20265108 | 0.81 | MAP4K4 (0.69) | MAP4K4EGFRKDRIRAK4PIK3CA | |
| SCHEMBL13495954 | 0.81 | MAP4K4 (1.00) | MAP4K4EGFRKDRIRAK4PIK3CA | |
| SCHEMBL25083972 | 0.77 | MAP4K4 (1.00) | MAP4K4EGFRKDRIRAK4PIK3CA | |
| SCHEMBL25269760 | 0.75 | MAP4K4 (0.68) | MAP4K4EGFRKDRIRAK4PIK3CA | |
| SCHEMBL25272642 | 0.74 | MAP4K4 (0.62) | MAP4K4EGFRKDRIRAK4PIK3CA | |
| SCHEMBL4046755 | 0.74 | EGFR (0.71) | MAP4K4EGFRKDRIRAK4AAK1 | |
| SCHEMBL26397070 | 0.73 | MAP4K4 (0.60) | MAP4K4EGFRKDRIRAK4PIK3CA | |
| SCHEMBL17130415 | 0.72 | MAP4K4 (0.62) | MAP4K4EGFRKDRIRAK4PIK3CA | |
| SCHEMBL15718766 | 0.72 | MAP4K4 (0.59) | MAP4K4EGFRKDRIRAK4PIK3CA | |
| SCHEMBL864036 | 0.71 | MAP4K4 (0.60) | MAP4K4EGFRKDRIRAK4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BIOCRYST PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | MAP4K4 3823/4885EGFR 2988/4885KDR 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.